GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » Shiller PE Ratio

Aurobindo Pharma (NSE:AUROPHARMA) Shiller PE Ratio : 20.49 (As of May. 15, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma Shiller PE Ratio?

As of today (2024-05-15), Aurobindo Pharma's current share price is ₹1168.60. Aurobindo Pharma's E10 for the quarter that ended in Dec. 2023 was ₹57.03. Aurobindo Pharma's Shiller PE Ratio for today is 20.49.

The historical rank and industry rank for Aurobindo Pharma's Shiller PE Ratio or its related term are showing as below:

NSE:AUROPHARMA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 7.8   Med: 15.4   Max: 24.3
Current: 19.77

During the past years, Aurobindo Pharma's highest Shiller PE Ratio was 24.30. The lowest was 7.80. And the median was 15.40.

NSE:AUROPHARMA's Shiller PE Ratio is ranked better than
62.92% of 534 companies
in the Drug Manufacturers industry
Industry Median: 25.25 vs NSE:AUROPHARMA: 19.77

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Aurobindo Pharma's adjusted earnings per share data for the three months ended in Dec. 2023 was ₹16.040. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ₹57.03 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aurobindo Pharma Shiller PE Ratio Historical Data

The historical data trend for Aurobindo Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Shiller PE Ratio Chart

Aurobindo Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 11.59 19.83 14.06 9.82

Aurobindo Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.46 9.82 13.24 16.34 19.01

Competitive Comparison of Aurobindo Pharma's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Shiller PE Ratio falls into.



Aurobindo Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aurobindo Pharma's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=1168.60/57.03
=20.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurobindo Pharma's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Aurobindo Pharma's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=16.04/153.2548*153.2548
=16.040

Current CPI (Dec. 2023) = 153.2548.

Aurobindo Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 8.605 91.425 14.424
201406 7.120 94.103 11.596
201409 6.380 96.780 10.103
201412 6.580 96.780 10.420
201503 6.920 97.163 10.915
201506 8.090 99.841 12.418
201509 7.760 101.753 11.688
201512 9.310 102.901 13.866
201603 9.490 102.518 14.187
201606 9.990 105.961 14.449
201609 10.400 105.961 15.042
201612 9.880 105.196 14.394
201703 9.100 105.196 13.257
201706 8.850 107.109 12.663
201709 13.330 109.021 18.738
201712 10.160 109.404 14.232
201803 9.020 109.786 12.591
201806 7.780 111.317 10.711
201809 10.440 115.142 13.896
201812 12.150 115.142 16.172
201903 9.990 118.202 12.953
201906 10.850 120.880 13.756
201909 10.920 123.175 13.587
201912 12.040 126.235 14.617
202003 14.750 124.705 18.127
202006 13.320 127.000 16.074
202009 13.780 130.118 16.230
202012 50.310 130.889 58.907
202103 13.590 131.771 15.806
202106 13.140 134.084 15.019
202109 11.890 135.847 13.414
202112 10.320 138.161 11.447
202203 9.830 138.822 10.852
202206 8.880 142.347 9.560
202209 6.990 144.661 7.405
202212 8.380 145.763 8.811
202303 8.640 146.865 9.016
202306 9.740 150.280 9.933
202309 12.830 151.492 12.979
202312 16.040 153.255 16.040

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aurobindo Pharma  (NSE:AUROPHARMA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aurobindo Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma (NSE:AUROPHARMA) Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (NSE:AUROPHARMA) Headlines

No Headlines